RxDoctor Payments Data

James Alonso, MD

Neurology · Saint Louis, MONPI 1063506566

Payments from drug & device makers

$12,769in general payments, 2019–2025

Across 841 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Supernus Pharmaceuticals, Inc.$774
  • Pfizer$625
  • Amneal Pharmaceuticals LLC$611
  • Novartis$506
  • Lilly USA, LLC$474
  • plus $6K from 51 others

What the payments were for

  • Speaking & faculty fees$410%
  • Food & beverage$12,64999%
  • Education$791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,769 in reported general payments places this provider in the 70th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$153,911
Medicare patients
514
Services billed
6,981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)25$89,013
FycompaPerampanel16$63,915
AptiomEslicarbazepine Acetate31$47,599
EliquisApixaban44$25,683
NourianzIstradefylline13$25,093
Aimovig AutoinjectorErenumab-Aooe18$13,158
Clobazam27$10,610
Levetiracetam226$9,484
Carbamazepine ErCarbamazepine42$8,524
Felbamate16$4,845
Divalproex Sodium83$4,277
Topiramate151$3,699
Gabapentin164$3,118
Pregabalin85$3,087
Carbamazepine30$2,782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$49$63,91516 claims
PfizerEliquis, Dilantin$625$27,86055 claims
Kyowa Kirin, Inc.Nourianz$126$25,09313 claims
Upsher-smith Laboratories LLCTopiramate$77$3,699151 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$611$1,81522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 381 neurology providers in Missouri.

Other neurology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →